Tonix Pharmaceuticals' shares reach $60 milestone ahead of FDA deadline, potential 65% approval.

Tonix Pharmaceuticals' stock has surpassed the $60 mark after crossing the FDA deadline. As a finance expert with experience at Bloomberg, I see a 65% approval potential for the company. The investment thesis highlights the significant developments in the stock since June and the milestone achieved in pre-market shares.

Tonix Pharmaceuticals' stock (NASDAQ: TNXP) has seen a significant rise, surpassing the $60 mark after the company crossed the FDA deadline. As a finance expert with experience at Bloomberg, I see a 65% approval potential for Tonix Pharmaceuticals, driven by substantial developments since June and the milestone achieved in pre-market shares.

The stock's surge can be attributed to several key factors. First, Tonix Pharmaceuticals has been on a tear in 2025, ripping more than 570%* [1]. The momentum has been fueled by a five-year agreement with the U.S. Department of Defense worth up to $34 million to advance TNX-4200, an oral broad-spectrum antiviral designed for use in biological threat scenarios [1]. This contract, through the Defense Threat Reduction Agency (DTRA), validates Tonix Pharmaceuticals' position in the high-stakes, government-backed biotech space.

Additionally, the stock's float of just 7 million shares has led to outsized moves when demand spikes [1]. The recent inclusion in the Russell 2000® and 3000® indexes has also drawn in fresh institutional buyers, boosting liquidity and further supporting the stock's rise [1].

The FDA decision on TNX-102 SL for fibromyalgia, scheduled for August 15, 2025, is another key catalyst. With Fast Track status already in place, a favorable decision could spark a major reaction in the stock [1]. This potential FDA approval, combined with the company's strong trend momentum and low float, makes Tonix Pharmaceuticals a prime biotech watch heading into a critical month.

In conclusion, Tonix Pharmaceuticals' stock has seen significant growth due to a combination of strong sector themes, high-impact catalysts, and a favorable regulatory environment. While the stock's future performance remains uncertain, the current data suggests a strong bullish case for investors to consider.

References:
[1] https://www.timothysykes.com/blog/biotech-penny-stocks/